Andrew Kang sold $3.9M of MSTR
EVP & CFO at Strategy Inc. 33,062 shares at an average of $118.73, traded Jun 5, 2026, filed Jun 5, 2026.
Score components
- +22RoleCFO
- +25Trade size$3.9M at market
- +10Share of holdings soldSold 32% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001825170-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | MOption exercise Class A Common Stock10b5-1 | +68,120 | $0.00 | $0 | 101,795 | Jun 5, 2026 |
| Jun 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -582 | $114.79 | $67k | 101,213 | Jun 5, 2026 |
| Jun 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -3,781 | $115.35 | $436k | 97,432 | Jun 5, 2026 |
| Jun 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -4,638 | $116.57 | $541k | 92,794 | Jun 5, 2026 |
| Jun 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -5,605 | $117.53 | $659k | 87,189 | Jun 5, 2026 |
| Jun 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -5,627 | $118.59 | $667k | 81,562 | Jun 5, 2026 |
| Jun 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -5,750 | $119.53 | $687k | 75,812 | Jun 5, 2026 |
| Jun 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -1,361 | $120.22 | $164k | 74,451 | Jun 5, 2026 |
| Jun 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -413 | $121.59 | $50k | 74,038 | Jun 5, 2026 |
| Jun 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -2,075 | $122.55 | $254k | 71,963 | Jun 5, 2026 |
| Jun 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -1,320 | $123.39 | $163k | 70,643 | Jun 5, 2026 |
| Jun 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -1,814 | $124.24 | $225k | 68,829 | Jun 5, 2026 |
| Jun 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -96 | $125.14 | $12k | 68,733 | Jun 5, 2026 |
| Jun 3, 2026 | MOption exercise Performance Stock Unitderivative10b5-1 | -68,120 | $0.00 | $0 | 0 | Jun 5, 2026 |
Related signals
Other insiders at Strategy Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 9Weak | MSTRsell Strategy Inc | Jarrod M Patten director | $81k 475 shares | -2% | |
| 13Weak | MSTRsell Strategy Inc | Jarrod M Patten director | $238k 1,425 shares | -5% | |
| 43Moderate | Strategy Inc | Thomas C. Chow EVP & General Counsel | $15k 106 shares | -100% | |
| 21Weak | Strategy Inc | Jarrod M Patten director | $241k 1,850 shares | -6% | |
| 30Weak | Strategy Inc | Jarrod M Patten director | $461k 3,700 shares | -13% | |
| 21Weak | MSTRsell Strategy Inc | Jarrod M Patten director | $389k 3,800 shares | -13% | |
| 20Weak | MSTRsell Strategy Inc | Jarrod M Patten director | $372k 3,900 shares | -13% | |
| 10Weak | MSTRsell Strategy Inc | Jarrod M Patten director | $125k 1,250 shares | -4% | |
| 26Weak | Strategy Inc | Jarrod M Patten director | $159k 1,500 shares | -5% | |
| 84Strong | Strategy Inc | Phong Le President & CEO | $999k 11,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.